Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Benedetta De Ponte ContiInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.ORCID 0009-0004-4910-211X
Rebecca MarinoInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.
Tanja Rezzonico-JostInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.ORCID 0009-0000-2146-2237
Mattia ForcatoDepartment of Molecular Medicine, University of Padova, Padova 35121, Italy.ORCID 0000-0002-7383-6576
Davide ManganiInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.ORCID 0000-0001-5297-0234
Elisabetta NotarioInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council, Bari 70126, Italy.
Giorgio GargariDivision of Food Microbiology and Bioprocesses, Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan 20133, Italy.ORCID 0000-0001-9077-6328
Elena CarelliIstituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan 20122, Italy.
Andrea RinaldiInstitute of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona 6500, Switzerland.ORCID 0000-0003-3234-0563
Andrea RaimondiInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.ORCID 0000-0002-4563-386X
Simone MoroInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.ORCID 0000-0001-5199-8390
Marinella MarzanoInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council, Bari 70126, Italy.ORCID 0000-0002-9996-8817
Grazia VisciDepartment of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, Bari 70126, Italy.
Lisa PerruzzaInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.
Matteo RaneriInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.
Denise DallavalleInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.ORCID 0009-0005-1629-5899
Giacomo MantegazzaDivision of Food Microbiology and Bioprocesses, Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan 20133, Italy.ORCID 0000-0002-0936-1211
Ludovica MontaniInfectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20123, Italy.
Francesco PriscoLaboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich 8057, Switzerland.ORCID 0000-0002-0399-1239
Roshan TakurInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.ORCID 0000-0001-5284-4975
Jens GeginatIstituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan 20122, Italy.ORCID 0000-0003-4813-0384
Frauke SeehusenLaboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich 8057, Switzerland.ORCID 0000-0001-6701-7868
Samuele NotarbartoloInfectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20123, Italy.ORCID 0000-0001-5910-4910
Graziano PesoleInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council, Bari 70126, Italy.ORCID 0000-0003-3663-0859
Silvio BicciatoDepartment of Molecular Medicine, University of Padova, Padova 35121, Italy.ORCID 0000-0002-1944-7078
Simone GuglielmettiDepartment of Biotechnology and Biosciences (BtBs), University of Milano-Bicocca, Milan 20126, Italy.ORCID 0000-0002-8673-8190
Fabio GrassiInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.ORCID 0000-0003-3348-1712
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The gut microbiota is essential for many aspects of host physiology, and secretory immunoglobulin A (sIgA) modulates its function. The microbiota community determines the efficacy of immune checkpoint blockade (ICB) in cancer immunotherapy; however, mechanisms able to improve this function are not known. Extracellular adenosine triphosphate (ATP) released by the microbiota restricts the sIgA repertoire by limiting T follicular helper (T
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Secretory IgA amplification during immune checkpoint blockade enhances the control of tumor growth by enterotropic T cells. · full record | OpenQuestion